Summary

Non-Hodgkin’s Lymphoma Therapeutics Market – Scope of Report
TMR’s report on the global non-Hodgkin’s lymphoma therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global non-Hodgkin’s lymphoma therapeutics market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global non-Hodgkin’s lymphoma therapeutics market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the non-Hodgkin’s lymphoma therapeutics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global non-Hodgkin’s lymphoma therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global non-Hodgkin’s lymphoma therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global non-Hodgkin’s lymphoma therapeutics market.

The report delves into the competitive landscape of the global non-Hodgkin’s lymphoma therapeutics market. Key players operating in the global non-Hodgkin’s lymphoma therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global non-Hodgkin’s lymphoma therapeutics market profiled in this report.

Key Questions Answered in Global non-Hodgkin’s lymphoma therapeutics Market Report
• What is the sales/revenue generated by non-Hodgkin’s lymphoma therapeutics across all regions during the forecast period?
• What are the opportunities in the global non-Hodgkin’s lymphoma therapeutics market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Non-Hodgkin’s Lymphoma Therapeutics Market – Research Objectives and Research Approach
The comprehensive report on the global non-Hodgkin’s lymphoma therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global non-Hodgkin’s lymphoma therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global non-Hodgkin’s lymphoma therapeutics market.

ページTOPに戻る

Table of Contents

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Non-Hodgkin’s Lymphoma Therapeutics Market
4. Market Overview
    4.1. Introduction
        4.1.1. Product Definition
        4.1.2. Industry Evolution / Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Non-Hodgkin’s Lymphoma Therapeutics Market Analysis and Forecast, 2020-2034
5. Key Insights
    5.1. Pipeline Analysis
    5.2. Key Product/Brand Analysis
    5.3. Key Mergers & Acquisitions
    5.4. COVID-19 Pandemic Impact on Industry
6. Global Non-Hodgkin’s Lymphoma Therapeutics Market Analysis and Forecast, by Treatment Therapy
    6.1. Introduction and Definitions
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Treatment Therapy, 2020-2034
        6.3.1. Chemotherapy
        6.3.2. Targeted Therapy
        6.3.3. Immunotherapy
        6.3.4. Others (Radiation Therapy, etc.)
    6.4. Market Attractiveness, by Treatment Therapy
7. Global Non-Hodgkin’s Lymphoma Therapeutics Market Analysis and Forecast, by Indication Type
    7.1. Introduction and Definitions
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Indication Type, 2020-2034
        7.3.1. B-Cell Lymphomas
        7.3.2. T-Cell Lymphomas
    7.4. Market Attractiveness, by Indication Type
8. Global Non-Hodgkin’s Lymphoma Therapeutics Market Analysis and Forecast, by Route of Administration
    8.1. Introduction and Definitions
    8.2. Key Findings/Developments
    8.3. Market Value Forecast, by Route of Administration, 2020-2034
        8.3.1. Oral
        8.3.2. Parenteral
    8.4. Market Attractiveness, by Route of Administration
9. Global Non-Hodgkin’s Lymphoma Therapeutics Market Analysis and Forecast, by End-user
    9.1. Introduction and Definitions
    9.2. Key Findings/Developments
    9.3. Market Value Forecast, by End-user, 2020-2034
        9.3.1. Hospital Pharmacies
        9.3.2. Retail Pharmacies
        9.3.3. Online Pharmacies
    9.4. Market Attractiveness, by End-user
10. Global Non-Hodgkin’s Lymphoma Therapeutics Market Analysis and Forecast, by Region
    10.1. Key Findings
    10.2. Market Value Forecast, by Region, 2020-2034
        10.2.1. North America
        10.2.2. Europe
        10.2.3. Asia Pacific
        10.2.4. Latin America
        10.2.5. Middle East & Africa
    10.3. Market Attractiveness, by Region
11. North America Non-Hodgkin’s Lymphoma Therapeutics Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Treatment Therapy, 2020-2034
        11.2.1. Chemotherapy
        11.2.2. Targeted Therapy
        11.2.3. Immunotherapy
        11.2.4. Others (Radiation Therapy, etc.)
    11.3. Market Attractiveness, by Treatment Therapy
    11.4. Market Value Forecast, by Indication Type, 2020-2034
        11.4.1. B-Cell Lymphomas
        11.4.2. T-Cell Lymphomas
    11.5. Market Attractiveness, by Indication Type
    11.6. Market Value Forecast, by Route of Administration, 2020-2034
        11.6.1. Oral
        11.6.2. Parenteral
    11.7. Market Attractiveness, by Route of Administration
    11.8. Market Value Forecast, by End-user, 2020-2034
        11.8.1. Hospital Pharmacies
        11.8.2. Retail Pharmacies
        11.8.3. Online Pharmacies
    11.9. Market Attractiveness, by End-user
    11.10. Market Value Forecast, by Country/Sub-region, 2020-2034
        11.10.1. U.S.
        11.10.2. Canada
    11.11. Market Attractiveness Analysis
        11.11.1. By Treatment Therapy
        11.11.2. By Indication Type
        11.11.3. By Route of Administration
        11.11.4. By End-user
        11.11.5. By Country
12. Europe Non-Hodgkin’s Lymphoma Therapeutics Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Treatment Therapy, 2020-2034
        12.2.1. Chemotherapy
        12.2.2. Targeted Therapy
        12.2.3. Immunotherapy
        12.2.4. Others (Radiation Therapy, etc.)
    12.3. Market Attractiveness, by Treatment Therapy
    12.4. Market Value Forecast, by Indication Type, 2020-2034
        12.4.1. B-Cell Lymphomas
        12.4.2. T-Cell Lymphomas
    12.5. Market Attractiveness, by Indication Type
    12.6. Market Value Forecast, by Route of Administration, 2020-2034
        12.6.1. Oral
        12.6.2. Parenteral
    12.7. Market Attractiveness, by Route of Administration
    12.8. Market Value Forecast, by End-user, 2020-2034
        12.8.1. Hospital Pharmacies
        12.8.2. Retail Pharmacies
        12.8.3. Online Pharmacies
    12.9. Market Attractiveness, by End-user
    12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
        12.10.1. Germany
        12.10.2. U.K.
        12.10.3. France
        12.10.4. Italy
        12.10.5. Spain
        12.10.6. Rest of Europe
    12.11. Market Attractiveness Analysis
        12.11.1. By Treatment Therapy
        12.11.2. By Indication Type
        12.11.3. By Route of Administration
        12.11.4. By End-user
        12.11.5. By Country/Sub-region
13. Asia Pacific Non-Hodgkin’s Lymphoma Therapeutics Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Treatment Therapy, 2020-2034
        13.2.1. Chemotherapy
        13.2.2. Targeted Therapy
        13.2.3. Immunotherapy
        13.2.4. Others (Radiation Therapy, etc.)
    13.3. Market Attractiveness, by Treatment Therapy
    13.4. Market Value Forecast, by Indication Type, 2020-2034
        13.4.1. B-Cell Lymphomas
        13.4.2. T-Cell Lymphomas
    13.5. Market Attractiveness, by Indication Type
    13.6. Market Value Forecast, by Route of Administration, 2020-2034
        13.6.1. Oral
        13.6.2. Parenteral
    13.7. Market Attractiveness, by Route of Administration
    13.8. Market Value Forecast, by End-user, 2020-2034
        13.8.1. Hospital Pharmacies
        13.8.2. Retail Pharmacies
        13.8.3. Online Pharmacies
    13.9. Market Attractiveness, by End-user
    13.10. Market Value Forecast, by Country/Sub-region, 2020-2034
        13.10.1. China
        13.10.2. Japan
        13.10.3. India
        13.10.4. Australia & New Zealand
        13.10.5. Rest of Asia Pacific
    13.11. Market Attractiveness Analysis
        13.11.1. By Treatment Therapy
        13.11.2. By Indication Type
        13.11.3. By Route of Administration
        13.11.4. By End-user
        13.11.5. By Country/Sub-region
14. Latin America Non-Hodgkin’s Lymphoma Therapeutics Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Treatment Therapy, 2020-2034
        14.2.1. Chemotherapy
        14.2.2. Targeted Therapy
        14.2.3. Immunotherapy
        14.2.4. Others (Radiation Therapy, etc.)
    14.3. Market Attractiveness, by Treatment Therapy
    14.4. Market Value Forecast, by Indication Type, 2020-2034
        14.4.1. B-Cell Lymphomas
        14.4.2. T-Cell Lymphomas
    14.5. Market Attractiveness, by Indication Type
    14.6. Market Value Forecast, by Route of Administration, 2020-2034
        14.6.1. Oral
        14.6.2. Parenteral
    14.7. Market Attractiveness, by Route of Administration
    14.8. Market Value Forecast, by End-user, 2020-2034
        14.8.1. Hospital Pharmacies
        14.8.2. Retail Pharmacies
        14.8.3. Online Pharmacies
    14.9. Market Attractiveness, by End-user
    14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
        14.10.1. Brazil
        14.10.2. Mexico
        14.10.3. Rest of Latin America
    14.11. Market Attractiveness Analysis
        14.11.1. By Treatment Therapy
        14.11.2. By Indication Type
        14.11.3. By Route of Administration
        14.11.4. By End-user
        14.11.5. By Country/Sub-region
15. Middle East & Africa Non-Hodgkin’s Lymphoma Therapeutics Market Analysis and Forecast
    15.1. Introduction
        15.1.1. Key Findings
    15.2. Market Value Forecast, by Treatment Therapy, 2020-2034
        15.2.1. Chemotherapy
        15.2.2. Targeted Therapy
        15.2.3. Immunotherapy
        15.2.4. Others (Radiation Therapy, etc.)
    15.3. Market Attractiveness, by Treatment Therapy
    15.4. Market Value Forecast, by Indication Type, 2020-2034
        15.4.1. B-Cell Lymphomas
        15.4.2. T-Cell Lymphomas
    15.5. Market Attractiveness, by Indication Type
    15.6. Market Value Forecast, by Route of Administration, 2020-2034
        15.6.1. Oral
        15.6.2. Parenteral
    15.7. Market Attractiveness, by Route of Administration
    15.8. Market Value Forecast, by End-user, 2020-2034
        15.8.1. Hospital Pharmacies
        15.8.2. Retail Pharmacies
        15.8.3. Online Pharmacies
    15.9. Market Attractiveness, by End-user
    15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
        15.10.1. GCC Countries
        15.10.2. South Africa
        15.10.3. Rest of Middle East & Africa
    15.11. Market Attractiveness Analysis
        15.11.1. By Treatment Therapy
        15.11.2. By Indication Type
        15.11.3. By Route of Administration
        15.11.4. By End-user
        15.11.5. By Country/Sub-region
16. Competition Landscape
    16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
    16.2. Market Share Analysis, by Company (2023)
    16.3. Company Profiles
        16.3.1. Mylan N.V.
            16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.1.2. Product Portfolio
            16.3.1.3. Financial Overview
            16.3.1.4. SWOT Analysis
            16.3.1.5. Strategic Overview
        16.3.2. Teva Pharmaceutical Industries Ltd.
            16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.2.2. Product Portfolio
            16.3.2.3. Financial Overview
            16.3.2.4. SWOT Analysis
            16.3.2.5. Strategic Overview
        16.3.3. Sanofi S.A.
            16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.3.2. Product Portfolio
            16.3.3.3. Financial Overview
            16.3.3.4. SWOT Analysis
            16.3.3.5. Strategic Overview
        16.3.4. Pfizer Inc.
            16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.4.2. Product Portfolio
            16.3.4.3. Financial Overview
            16.3.4.4. SWOT Analysis
            16.3.4.5. Strategic Overview
        16.3.5. GSK plc
            16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.5.2. Product Portfolio
            16.3.5.3. Financial Overview
            16.3.5.4. SWOT Analysis
            16.3.5.5. Strategic Overview
        16.3.6. Novartis AG
            16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.6.2. Product Portfolio
            16.3.6.3. Financial Overview
            16.3.6.4. SWOT Analysis
            16.3.6.5. Strategic Overview
        16.3.7. Bayer AG
            16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.7.2. Product Portfolio
            16.3.7.3. Financial Overview
            16.3.7.4. SWOT Analysis
            16.3.7.5. Strategic Overview
        16.3.8. Eli Lilly and Company
            16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.8.2. Product Portfolio
            16.3.8.3. Financial Overview
            16.3.8.4. SWOT Analysis
            16.3.8.5. Strategic Overview
        16.3.9. Merck & Co., Inc.
            16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.9.2. Product Portfolio
            16.3.9.3. Financial Overview
            16.3.9.4. SWOT Analysis
            16.3.9.5. Strategic Overview
        16.3.10. AbbVie Inc.
            16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.10.2. Product Portfolio
            16.3.10.3. Financial Overview
            16.3.10.4. SWOT Analysis
            16.3.10.5. Strategic Overview
        16.3.11. AstraZeneca plc
            16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.11.2. Product Portfolio
            16.3.11.3. Financial Overview
            16.3.11.4. SWOT Analysis
            16.3.11.5. Strategic Overview
        16.3.12. Johnson & Johnson Pvt. Ltd.
            16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.12.2. Product Portfolio
            16.3.12.3. Financial Overview
            16.3.12.4. SWOT Analysis
            16.3.12.5. Strategic Overview